Sera Prognostics Inc. announced the execution of an agreement with MultiPlan, for participation in its PHCS and MultiPlan Networks. The agreement will help expand access to the PreTRM® Test, the company's proprietary proteomic blood test for measuring a woman's risk of spontaneous preterm birth, to allow more timely intervention to the members accessing MultiPlan's services through its more than 700 healthcare payers and the 1.2 million healthcare providers participating in MultiPlan's provider networks. The PreTRM® Test is the only broadly clinically validated, commercially available blood-based biomarker test that provides an early, accurate, and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies.

Ordered by medical professionals, the test empowers physicians to better identify, during the 19th or 20th week of pregnancy, women who are at increased risk for premature delivery. This early knowledge enables these women and their doctors to develop personalized intervention plans designed to improve the outcomes of newborns and mothers.